卖什么
癌症生物标志物检测器。
商业模式拆解
买家：谁掌握预算？
未核实Lab heads / core-facility managers purchasing benchtop instruments and consumables.
触发点：什么让他们现在购买？
Need to identify, count and sort nano-objects that conventional flow cytometers cannot, e.g. for EV biomarker development.
工作流：什么输入变成什么输出？
Load a 50 microliter sample, count in about 2 minutes (NanoCounter) or sort subpopulations with dual-color fluorescence (NanoSorter), harvest concentrated output for omics or functional assays; export .csv/.fcs with automated reporting.
经济账：省了什么，怎么收费？
Instrument sales (NanoCounter, NanoSorter) plus recurring consumables (chips, packs, oil) and in-house sample services.
渠道：怎么接触到客户？
Direct quote-based sales ("Request a quote"), conferences and publications.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| 2026-07-21 | — | 2,4 millions d'euros | — | news.google.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.